Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
10.1016/j.drugpo.2023.104139 42 PoplawskaM.BednarekE.NaumczukB.BlazewiczA
*Correspondence: Yi Hua, [email protected] This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
In the obese trial cohort, 1 mg moved 24-hour ambulatory heart rate by +0.7 bpm at week 24 the peak of the heart-rate curve, and below the placebo arms +0.8. In a healthy lean Phase 1 group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
Rather than focusing on a single pathway, current studies explore how the peptide interacts with multiple biological systems under controlled laboratory conditions
